Mounjaro, the breakthrough obesity and diabetes drug from Eli Lilly and Company, has become India’s highest-selling pharmaceutical brand in October, according to fresh data from market intelligence firm Pharmarack released on November 7.

The blockbuster medication, which contains tirzepatide as its active ingredient, recorded sales worth Rs100 crore last month, surpassing long-time market leader Augmentin, the antibiotic that traditionally dominates India’s monthly drug sales charts.

Launched in March 2025, Mounjaro has already amassed cumulative revenues of 333 crore till October this year, signaling unprecedented demand in India’s rapidly expanding anti-obesity market.

Just days ago, Eli Lilly announced plans to expand Mounjaro’s reach under a new brand name, Yurpeak, in collaboration

See Full Page